Elena Wolff-Holz

1 week ago | centerforbiosimilars.com | Cameron Santoro |Elena Wolff-Holz

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, supports automatic substitution of biosimilars at the pharmacy, citing that Europe often grants this immediately with marketing authorization. She highlights interchangeability in the US specifically refers to automatic substitution, and BMAb-1200 (Yesintek; ustekinumab-kfce), has achieved this status.

4 weeks ago | centerforbiosimilars.com | Cameron Santoro |Elena Wolff-Holz

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200 (Yesintek; ustekinumab-kfce), for psoriasis treatment, a biosimilar referencing Stelara (ustekinumab). She highlighted the comparable efficacy and safety with reference Stelara, including positive switching data.